106 results
Page 2 of 6
ARS
8uv4ujg6zuhb
1 May 23
Annual report to shareholders
1:52pm
424B5
392rco4fud5
14 Sep 22
Prospectus supplement for primary offering
4:12pm
424B5
fumyd4
13 Sep 22
Prospectus supplement for primary offering
5:19pm
8-K
EX-99.1
yv63ijb1c tvrx8
12 Sep 22
POINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial in mCRPC at ESMO Congress 2022
7:54am
8-K
EX-99.2
r61xr51i0t
12 Sep 22
POINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial in mCRPC at ESMO Congress 2022
7:54am
424B3
ogugq5yy
11 Jul 22
Prospectus supplement
4:32pm
POS AM
8waprtl
1 Jul 22
Prospectus update (post-effective amendment)
4:17pm
S-3
2dg0p 87s5lfncqt3
1 Jul 22
Shelf registration
4:13pm
S-3
EX-1.2
bphlg
1 Jul 22
Shelf registration
4:13pm
S-3
EX-4.6
4bcp62
1 Jul 22
Shelf registration
4:13pm
S-3
EX-4.7
6c8qh0z5
1 Jul 22
Shelf registration
4:13pm
424B3
5o9t9q
13 May 22
Prospectus supplement
8:18am
DEF 14A
gotzp0d0yhwqp1122 of
28 Apr 22
Definitive proxy
8:36am